JMV 2959 does not cause any intracellular calcium mobilization by itself[1].

JMV 2959 dose-dependently reduces the startle response (F(3.42)=4.4, p<0.01) and enhances prepulse inhibition (PPI) (F(3.42)=3.9, p<0.05) in the prepulse inhibition paradigm. JMV 2959 (6 mg/kg) causes a obviously suppression of locomotion on days 1 to 7 relative to baseline day 0 (F(7,49)=2.21, p<0.05). When administered alone, it does not increase food intake and does not obviously stimulate growth hormone (GH) release[1]. The alteration in the startle response is mainly due to a 27% decrease in the startle seen in the highest dose of JMV 2959 (6 mg/kg) compare to vehicle (p<0.05)[2]. Results also reveal a significant interaction between JMV 2959 treatment and day (F(1,14)=4.397, p<0.05)[3].